Login to Your Account



Other News To Note


Tuesday, October 18, 2011
Capstone Therapeutics, of Tempe, Ariz., is cutting 14 of its 18 full-time employees to preserve cash during ongoing discussions with potential partners for dermal scarring drug AZX100. The company has been struggling since Phase IIa trials fell short of statistical significance last year.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription